PMC:7344504 / 837-2041 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T7","span":{"begin":33,"end":57},"obj":"Disease"},{"id":"T8","span":{"begin":59,"end":67},"obj":"Disease"},{"id":"T9","span":{"begin":154,"end":167},"obj":"Disease"},{"id":"T10","span":{"begin":177,"end":186},"obj":"Disease"},{"id":"T11","span":{"begin":192,"end":200},"obj":"Disease"},{"id":"T12","span":{"begin":222,"end":235},"obj":"Disease"},{"id":"T13","span":{"begin":237,"end":241},"obj":"Disease"},{"id":"T14","span":{"begin":507,"end":511},"obj":"Disease"},{"id":"T15","span":{"begin":588,"end":592},"obj":"Disease"},{"id":"T16","span":{"begin":670,"end":679},"obj":"Disease"},{"id":"T17","span":{"begin":687,"end":696},"obj":"Disease"},{"id":"T18","span":{"begin":786,"end":799},"obj":"Disease"},{"id":"T19","span":{"begin":945,"end":967},"obj":"Disease"},{"id":"T20","span":{"begin":954,"end":967},"obj":"Disease"},{"id":"T21","span":{"begin":1140,"end":1148},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"There have been suggestions that coronavirus disease 2019 (COVID-19) might increase the risk of superinfections [1] and, particularly, invasive pulmonary aspergillosis (IPA) co-infection [2]. COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients in intensive care unit (ICUs) with severe pulmonary abnormalities. Small cohorts of 31 patients in the Netherlands [3], 27 patients in France [4] and 19 patients in Germany [5] have been published, showing CAPA rates of 19.4%, 33% and 26%, respectively. An additional two fatal cases of CAPA were recently reported [6,7]. The numbers resemble what has been observed in influenza, where influenza in ICU patients has been identified as an independent risk factor for invasive pulmonary aspergillosis and which is associated with an even higher mortality rate than IPA alone [8]. In addition, in the Netherlands, an estimated 11.3% of cases with invasive aspergillosis are infected with an azole-resistant isolate [9], potentially increasing mortality to 50–100% [10]. We present the first case of azole-resistant Aspergillus fumigatus in a SARS-CoV-2-positive immunocompetent patient admitted to the ICU."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":246,"end":247},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":421,"end":423},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T9","span":{"begin":649,"end":652},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T10","span":{"begin":713,"end":716},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T11","span":{"begin":1138,"end":1139},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"There have been suggestions that coronavirus disease 2019 (COVID-19) might increase the risk of superinfections [1] and, particularly, invasive pulmonary aspergillosis (IPA) co-infection [2]. COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients in intensive care unit (ICUs) with severe pulmonary abnormalities. Small cohorts of 31 patients in the Netherlands [3], 27 patients in France [4] and 19 patients in Germany [5] have been published, showing CAPA rates of 19.4%, 33% and 26%, respectively. An additional two fatal cases of CAPA were recently reported [6,7]. The numbers resemble what has been observed in influenza, where influenza in ICU patients has been identified as an independent risk factor for invasive pulmonary aspergillosis and which is associated with an even higher mortality rate than IPA alone [8]. In addition, in the Netherlands, an estimated 11.3% of cases with invasive aspergillosis are infected with an azole-resistant isolate [9], potentially increasing mortality to 50–100% [10]. We present the first case of azole-resistant Aspergillus fumigatus in a SARS-CoV-2-positive immunocompetent patient admitted to the ICU."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T8","span":{"begin":169,"end":172},"obj":"Chemical"},{"id":"T10","span":{"begin":864,"end":867},"obj":"Chemical"},{"id":"T12","span":{"begin":989,"end":994},"obj":"Chemical"},{"id":"T13","span":{"begin":1097,"end":1102},"obj":"Chemical"}],"attributes":[{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A9","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A11","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_68452"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_68452"}],"text":"There have been suggestions that coronavirus disease 2019 (COVID-19) might increase the risk of superinfections [1] and, particularly, invasive pulmonary aspergillosis (IPA) co-infection [2]. COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients in intensive care unit (ICUs) with severe pulmonary abnormalities. Small cohorts of 31 patients in the Netherlands [3], 27 patients in France [4] and 19 patients in Germany [5] have been published, showing CAPA rates of 19.4%, 33% and 26%, respectively. An additional two fatal cases of CAPA were recently reported [6,7]. The numbers resemble what has been observed in influenza, where influenza in ICU patients has been identified as an independent risk factor for invasive pulmonary aspergillosis and which is associated with an even higher mortality rate than IPA alone [8]. In addition, in the Netherlands, an estimated 11.3% of cases with invasive aspergillosis are infected with an azole-resistant isolate [9], potentially increasing mortality to 50–100% [10]. We present the first case of azole-resistant Aspergillus fumigatus in a SARS-CoV-2-positive immunocompetent patient admitted to the ICU."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":191},"obj":"Sentence"},{"id":"T12","span":{"begin":192,"end":367},"obj":"Sentence"},{"id":"T13","span":{"begin":368,"end":554},"obj":"Sentence"},{"id":"T14","span":{"begin":555,"end":622},"obj":"Sentence"},{"id":"T15","span":{"begin":623,"end":878},"obj":"Sentence"},{"id":"T16","span":{"begin":879,"end":1067},"obj":"Sentence"},{"id":"T17","span":{"begin":1068,"end":1204},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"There have been suggestions that coronavirus disease 2019 (COVID-19) might increase the risk of superinfections [1] and, particularly, invasive pulmonary aspergillosis (IPA) co-infection [2]. COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients in intensive care unit (ICUs) with severe pulmonary abnormalities. Small cohorts of 31 patients in the Netherlands [3], 27 patients in France [4] and 19 patients in Germany [5] have been published, showing CAPA rates of 19.4%, 33% and 26%, respectively. An additional two fatal cases of CAPA were recently reported [6,7]. The numbers resemble what has been observed in influenza, where influenza in ICU patients has been identified as an independent risk factor for invasive pulmonary aspergillosis and which is associated with an even higher mortality rate than IPA alone [8]. In addition, in the Netherlands, an estimated 11.3% of cases with invasive aspergillosis are infected with an azole-resistant isolate [9], potentially increasing mortality to 50–100% [10]. We present the first case of azole-resistant Aspergillus fumigatus in a SARS-CoV-2-positive immunocompetent patient admitted to the ICU."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":135,"end":167},"obj":"Phenotype"},{"id":"T2","span":{"begin":169,"end":172},"obj":"Phenotype"},{"id":"T3","span":{"begin":767,"end":799},"obj":"Phenotype"},{"id":"T4","span":{"begin":864,"end":867},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"There have been suggestions that coronavirus disease 2019 (COVID-19) might increase the risk of superinfections [1] and, particularly, invasive pulmonary aspergillosis (IPA) co-infection [2]. COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients in intensive care unit (ICUs) with severe pulmonary abnormalities. Small cohorts of 31 patients in the Netherlands [3], 27 patients in France [4] and 19 patients in Germany [5] have been published, showing CAPA rates of 19.4%, 33% and 26%, respectively. An additional two fatal cases of CAPA were recently reported [6,7]. The numbers resemble what has been observed in influenza, where influenza in ICU patients has been identified as an independent risk factor for invasive pulmonary aspergillosis and which is associated with an even higher mortality rate than IPA alone [8]. In addition, in the Netherlands, an estimated 11.3% of cases with invasive aspergillosis are infected with an azole-resistant isolate [9], potentially increasing mortality to 50–100% [10]. We present the first case of azole-resistant Aspergillus fumigatus in a SARS-CoV-2-positive immunocompetent patient admitted to the ICU."}

2_test

{"project":"2_test","denotations":[{"id":"32517166-32361747-60114378","span":{"begin":113,"end":114},"obj":"32361747"},{"id":"32517166-32396381-60114379","span":{"begin":417,"end":418},"obj":"32396381"},{"id":"32517166-32339350-60114380","span":{"begin":475,"end":476},"obj":"32339350"},{"id":"32517166-30076119-60114381","span":{"begin":875,"end":876},"obj":"30076119"},{"id":"32517166-32297377-60114382","span":{"begin":1014,"end":1015},"obj":"32297377"}],"text":"There have been suggestions that coronavirus disease 2019 (COVID-19) might increase the risk of superinfections [1] and, particularly, invasive pulmonary aspergillosis (IPA) co-infection [2]. COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients in intensive care unit (ICUs) with severe pulmonary abnormalities. Small cohorts of 31 patients in the Netherlands [3], 27 patients in France [4] and 19 patients in Germany [5] have been published, showing CAPA rates of 19.4%, 33% and 26%, respectively. An additional two fatal cases of CAPA were recently reported [6,7]. The numbers resemble what has been observed in influenza, where influenza in ICU patients has been identified as an independent risk factor for invasive pulmonary aspergillosis and which is associated with an even higher mortality rate than IPA alone [8]. In addition, in the Netherlands, an estimated 11.3% of cases with invasive aspergillosis are infected with an azole-resistant isolate [9], potentially increasing mortality to 50–100% [10]. We present the first case of azole-resistant Aspergillus fumigatus in a SARS-CoV-2-positive immunocompetent patient admitted to the ICU."}